NextCure (NASDAQ:NXTC) Given New $4.00 Price Target at HC Wainwright

NextCure (NASDAQ:NXTC) had its price target reduced by HC Wainwright from $8.00 to $4.00 in a research report sent to investors on Monday,Benzinga reports. They currently have a buy rating on the stock.

Separately, Needham & Company LLC reissued a “buy” rating and issued a $4.00 price objective on shares of NextCure in a research report on Friday, August 2nd.

NextCure Trading Down 8.4 %

Shares of NXTC opened at $1.41 on Monday. The stock has a market cap of $39.49 million, a P/E ratio of -0.72 and a beta of 0.80. The company has a 50-day moving average of $1.37 and a two-hundred day moving average of $1.49. NextCure has a 12-month low of $1.03 and a 12-month high of $2.57.

Hedge Funds Weigh In On NextCure

A number of institutional investors have recently modified their holdings of the company. Armistice Capital LLC acquired a new position in shares of NextCure in the second quarter valued at approximately $57,000. Renaissance Technologies LLC increased its position in NextCure by 15.4% during the second quarter. Renaissance Technologies LLC now owns 462,144 shares of the company’s stock worth $735,000 after purchasing an additional 61,744 shares during the last quarter. Vanguard Group Inc. increased its position in NextCure by 9.3% during the first quarter. Vanguard Group Inc. now owns 987,324 shares of the company’s stock worth $2,202,000 after purchasing an additional 83,700 shares during the last quarter. Affinity Asset Advisors LLC increased its position in NextCure by 24.2% during the second quarter. Affinity Asset Advisors LLC now owns 1,687,955 shares of the company’s stock worth $2,684,000 after purchasing an additional 328,918 shares during the last quarter. Finally, Logos Global Management LP increased its position in NextCure by 29.9% during the second quarter. Logos Global Management LP now owns 2,500,000 shares of the company’s stock worth $3,975,000 after purchasing an additional 575,000 shares during the last quarter. Institutional investors and hedge funds own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.